GFR Measured with Computed Tomography for Platinum Treatment Decision-Making in Urothelial Carcinoma
Kidney360 · 13.11.2026
DOI: 10.34067/kid.0000001426 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney360, online erschienen am 13.11.2026. Verfasst von Juliette Poulain und 9 weiteren Autor:innen. Beteiligte Einrichtung: Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri-Mondor, Service d'Oncologie Médicale, Créteil, France. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Accurate assessment of glomerular filtration rate (GFR) is essential for cisplatin eligibility and carboplatin dosing. We recently demonstrated that GFR measured using iodinated contrast agent clearance derived from 4-phase CT urography (CT-mGFR) showed good agreement with iohexol clearance in both healthy individuals and patients with chronic kidney disease. We aimed to evaluate the impact of CT-mGFR on platinum selection and whether CT-mGFR-based carboplatin dosing might reduce toxicity in urothelial carcinoma.
Methods
This single-center retrospective cohort study included patients with urothelial carcinoma treated with platinum-based chemotherapy who had 4-phase CT urography within 6 months before cancer treatment and stable estimated GFR (eGFR). Primary endpoints were, first, the proportion of patients in whom CT-mGFR would have changed the choice between cisplatin and carboplatin compared with 2009 CKD-EPIcr based decision-making (equation used in routine clinical practice in France) using a 60 ml/min/1.73m 2 threshold, and second, the association between grade 3-4 carboplatin-related hematologic toxicity and the relative dose difference between CT-mGFR–predicted and administered doses. Relative dose differences within ±15% were considered concordant. Severe hematologic toxicity was defined as Common Terminology Criteria for Adverse Events grade 3–4. Associations were assessed using Fisher’s exact test and logistic regression.
Results
Forty-seven patients were included (79% male), with a median age of 69 years (IQR, 62–75). CT-mGFR and 2009 CKD-EPIcr–based eGFR led to discordant platinum treatment decisions in 10 patients (21%). The sensitivity and specificity of 2009 CKD-EPIcr for identifying CT-mGFR
Autor:innen und Institutionen
- Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri-Mondor, Service d'Oncologie Médicale, Créteil, France.
- Sorbonne University, Paris, France.
- Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri-Mondor, Service d'Imagerie Médicale, Créteil, France.
- Univ Paris Est Créteil, Institut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale (IMRB), Créteil, France.
- Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Paul Brousse, département d'Oncologie Médicale, Villejuif, France.
- Centre d'Oncologie St. Yves, Service d'Oncologie Medicale, Vannes, France.
ORCID-Profile: Juliette Poulain, Charlotte Fenioux, Charlotte Joly, Christophe Tournigand, Emmanuelle Kempf, Thomas Stehlé
Zitieren
APA
Poulain, J., Pigneur, F., Fenioux, C., Joly, C., Saldana, C., Aubert, M., Tournigand, C., Grimbert, P., Kempf, E., & Stehlé, T. (2026). GFR Measured with Computed Tomography for Platinum Treatment Decision-Making in Urothelial Carcinoma. Kidney360. https://doi.org/10.34067/kid.0000001426
Vancouver
Poulain J, Pigneur F, Fenioux C, Joly C, Saldana C, Aubert M, et al. GFR Measured with Computed Tomography for Platinum Treatment Decision-Making in Urothelial Carcinoma. Kidney360. 2026. doi:10.34067/kid.0000001426
BibTeX
@article{Poulain2026,
author = {Poulain, Juliette and Pigneur, Frédéric and Fenioux, Charlotte and Joly, Charlotte and Saldana, Carolina and Aubert, Marine and Tournigand, Christophe and Grimbert, Philippe and Kempf, Emmanuelle and Stehlé, Thomas},
title = {GFR Measured with Computed Tomography for Platinum Treatment Decision-Making in Urothelial Carcinoma},
journal = {Kidney360},
year = {2026},
doi = {10.34067/kid.0000001426}
}
EUVIMED